I'm Stephanie Helena. I am associate professor of hematology and internal medicine. And I'm the chief of hematology, and I focus on Mallard display. To me, the most important thing is to build a team that seamlessly transitioned from the clinic all the way to basic science that brings questions from the clinic to the basic science laboratories, and that brings innovation from the basic
science laboratories back to the patient.
NOTE Confidence: 0.8041331

Advancements in medicine.
NOTE Confidence: 0.8041331

A general in hematology have been.
NOTE Confidence: 0.8041331

Absolutely amazing and we are in a
NOTE Confidence: 0.8041331

phenomenal time for for innovation.
NOTE Confidence: 0.8041331

I think a lot of it comes from our
NOTE Confidence: 0.8041331

deepen understanding of diseases.
NOTE Confidence: 0.8041331

We have so many technologies at our
NOTE Confidence: 0.8041331

fingertips to understand what causes disease,
NOTE Confidence: 0.8041331

what drives disease,
NOTE Confidence: 0.8041331

what results in resistance is to therapies,
NOTE Confidence: 0.8041331

and as a result we can develop novel
NOTE Confidence: 0.8041331

therapies that we never had the
NOTE Confidence: 0.8041331

opportunity to do that are no longer these.
NOTE Confidence: 0.8041331

Sledge hammer chemotherapies but very
NOTE Confidence: 0.8041331

targeted at what drives the cancer.
One area that my laboratory is particularly interested in is how RNA modifications and we look at how this RNA is altered, for example through mutations and so called splicing factors or through abnormalities and RNA editing. And we have identified a couple of mechanisms in that area that we may be able to exploit in the therapy of hematologic diseases.